Stratifying the effects of SGLT2i: CARDIOPROTECTION
Stratifying the effects of SGLT2i: CARDIOPROTECTION
About this item
Full title
Stratifying the effects of SGLT2i: CARDIOPROTECTION
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Nature reviews cardiology, 2019-06, Vol.16 (6), p.322-322
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Two prespecified analyses of the DECLARE–TIMI 58 trial show that in patients with type 2 diabetes mellitus, dapagliflozin has greater cardiovascular benefit in those with heart failure with reduced ejection fraction at baseline and in those with prior myocardial infarction
Alternative Titles
Full title
Stratifying the effects of SGLT2i: CARDIOPROTECTION
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_springer_journals_10_1038_s41569_019_0198_x
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_springer_journals_10_1038_s41569_019_0198_x
Other Identifiers
ISSN
1759-5002
E-ISSN
1759-5010
DOI
10.1038/s41569-019-0198-x
How to access this item
Log in as a Library member
